Elucidation of the mechanism of Zhenbao pills for the treatment of spinal cord injury by network pharmacology and molecular docking

This review explores how Zhenbao pill (ZBP) might help treat spinal cord injuries (SCI) using computational methods to predict drug-target interactions. Researchers screened for active components and targets of ZBP, identified genes related to SCI, and predicted potential drug targets using databases and software. The study looked at how ZBP's components interact with SCI-related proteins and pathways, using molecular docking to see how well they bind.

• 1
  ZBP contains 391 active ingredients and targets 836 proteins, with 1557 genes related to spinal cord injury.
• 2
  Key active ingredients in ZBP include Quercetin, Camptothecin, and Kaempferol, which interact with core genes SRC, CTNNB1, TP53, AKT1, and STAT3.
• 3
  Molecular docking showed that CTNNB1, SRC, TP53, AKT1 and STAT3 showed good binding ability with quercetin, kaempferol and ethyl isobutyric acid, suggesting direct interaction.